Breast Cancer Treatment Surgeon Knoxville, TN - Dr. Aaron Margulies  FACS
  • Email
  • Facebook
  • Google
  • Linkedin
  • Pinterest
  • Twitter
  • Youtube
  • Rss
Passionate. Committed. Your Captain.
  • Home
  • About
    • About Dr. Aaron G. Margulies
    • About Director of Clinical Genetics Services: Imelda G. Margulies MSN, FNP-BC
  • Schedule Appointment
    • Download and Print Patient Forms
      • Dr. Aaron Margulies
        • Breast Care Consultations
        • General Surgery Consultations
      • Imelda Margulies
        • Genetic Counseling and High Risk In Office Consultations
        • Genetic Counseling and High Risk Telehealth Consultations
  • Leave Review
    • Contact
  • Patient Resources
    • Patient Portal
    • Cancer Risk Quiz
    • Dr. Margulies Explains Cancer
    • 5 Questions to ask the Radiologist About Breast Cancer Checklist
    • Hidden Scar Surgery
  • Patient Forms
    • Dr. Aaron Margulies
      • Breast Care Consultations
      • General Surgery Consultations
    • Imelda Margulies
      • Genetic Counseling and High Risk Genetic Counseling and High Risk In Office Consultations Consultations
      • Genetic Counseling and High Risk Telehealth Consultations
  • Cancer Risk Quiz
Search the site...
Home» Breast Cancer Treatment » Encouraging News For Treatment Of HER2-positive Early Breast Cancer

Encouraging News For Treatment Of HER2-positive Early Breast Cancer

Posted by Dr. Aaron G. Margulies - December 10, 2018 - Breast Cancer Treatment
0

I’m excited to share news about a significant advancement in treatment for patients with HER2-positive early breast cancer. A phase III trial shows that a treatment called Kadcyla® (TDM-1) lowered the risk of recurrence of invasive breast cancer or death by 50% compared to Herceptin® in patients with HER2-positive early breast cancer with residual disease after pre-surgical (neoadjuvant = NST) therapy.

Approximately 20% of all breast cancers are HER2-positive, which tend to be more aggressive than HER2-negative breast cancers. For patients with HER2–positive early breast cancer who received pre-surgical chemotherapy plus HER2-targeted therapy and still have residual invasive disease at the time of surgery, this state of residual disease is associated with a worse prognosis of recurrence or death.

Pre-surgical (neoadjuvant) treatment is given with the goal of shrinking tumors to help improve surgical outcomes and to monitor a tumors response to medical therapy. Post-surgical (adjuvant) treatment is given as part of a complete early breast cancer treatment regimen and is aimed at eliminating any remaining cancer cells in the body after surgery to help reduce the risk of the cancer returning.

In the trial, Kadcyla® was given to HER2-positive breast cancer patients who had residual disease in the breast and/or in axillary nodes following neoadjuvant treatment. Kadcyla®  has two cancer-fighting agents in one drug: the first agent is an anti-HER2 antibody, which delivers Kadcyla® to the breast cancer, and the second agent is a chemotherapy drug, which kills the breast cancer.

Like many cancer medicines, Kadcyla® is given by intravenous (IV) infusion at a doctor’s office, hospital, or infusion center at three week intervals.

At three years, 88.3% of people in the trial who were treated with Kadcyla® did not have their breast cancer return compared to 77% who were treated with Herceptin, an 11.3 percent improvement. Kadcyla® improved invasive disease-free survival rates regardless of hormone receptor status, lymph node status, and prior HER2-targeted treatment regimen received before surgery.

The results of the trial were presented at the 2018 San Antonio Breast Cancer Symposium on December 5th, published in the New England Journal of Medicine, and will be submitted to regulatory authorities around the world, including the FDA.

I’m very encouraged by these positive results with Kadcyla® treatment for people with HER2-positive early breast cancer who have residual disease after pre-surgical therapy, and I will be recommending that all my patients who have HER2-positive breast cancer measuring at least 1-cm in size receive chemotherapy with HER2 targeted therapy prior to surgery.

If you’d like to discuss advances in surgical treatments for breast cancer, I am happy to consult with you. Committed to serving breast cancer patients through my solo practice in Breast Surgical Oncology and General Surgery, I have offices at Tennova Turkey Creek Medical Center in West Knoxville, at Tennova North Knoxville Medical Center in Powell, at Jefferson Memorial Hospital, and in Newport. My extensive research and dedication to continual learning have distinguished me as a leader in the field. To learn more about my compassionate surgical care approach visit www.aaronmd.com or call (865) 692-1610.

 

  • Share
  • Facebook
  • Twitter
  • Pinterest
  • Email
  • Print
  • LinkedIn
  • Tumblr
clinical trials for HER2-positive breast cancer, Kadcyla

Dr. Margulies practices sees patients in West Knoxville at Turkey Creek Medical Center, in Powell just off of Emory Road​ adjacent to North Knoxville Medical Center in Powell, at Jefferson Memorial Hospital and Newport Medical Center.

Dr. Margulies performs surgeries at Tennova’s Turkey Creek Medical Center and North Knoxville Medical Center, at Jefferson Memorial Hospital, at Newport Medical Center and at Parkwest Medical Center.

Learn more about Dr. Margulies here.

Hidden Scar Provider

Click here to learn more about Hidden Scar Surgery.

Schedule an Appointment

If you need to request an appointment, please call (865) 692-1610 and ask for Dr. Aaron Margulies.

Connect with Me

  • (865) 692-1610
  • Contact Us
    • Facebook
    • Linkedin
    • Twitter
    • Pinterest
    • Youtube

Patient Testimonials

“Thank you for all you’ve done to teach me along this incredible journey.”

Kaitlin

“Thank you for your speedy surgery and compassionate care. My family could finally exhale.”

Emily

“Thank you for the excellent care I received as a patient under our care. I appreciate the kindness, utmost consideration and prompt treatment. I would definitely spread the word to friends and family.”

Lola

Thank you for being the exceptional doctor. By this I mean your thorough explanations, your caring manner and your hugs! I felt completely relaxed in your hands!

Jane

“I find it very comforting to have my surgeon pray with me and for me and call me himself to give reports on my condition. Thank you!”

Mary

Recent Articles

  • DCIS Treatment – What Are My Options?
  • What Is Actually Considered “Family History” Or “High Risk” Of Breast Cancer?
  • How Accurate Is Genetic Testing, And When Should You Consider It?
  • How Telemedicine Can Help With Breast Cancer Concerns During COVID-19 
  • What You Need To Know About Surgeries During The COVID-19 Pandemic

Search Articles

Topics

  • Breast Cancer Diagnosis
  • Breast Cancer Research
  • Breast Cancer Surgery
  • Breast Cancer Treatment
  • Cancer Survival
  • Genetic testing
  • Knoxville Community
  • Patient Stories

Resources

  • Abercrombie Radiology
  • American Board of Surgery
  • American College of Surgeons
  • American Society of Breast Surgeons
  • Breast 360
  • Breast Cancer Statistics
  • Breast Cancer Terms
  • Breast Connect
  • Knoxville Comprehensive Breast Center
  • Mastery of Breast Surgery
  • Society of Surgical Oncology
(c) 2020 Dr. Aaron Margulies - Web Design by Baker Labs
  • Home
  • About
  • Schedule Appointment
  • Leave Review
  • Patient Resources
  • Patient Forms
  • Cancer Risk Quiz
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.